Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bailing tablet is a multi-component patent Chinese medicine widely used in China for the treatment of vitiligo. Its therapeutic effects are attributed to its ability to regulate immune inflammation, apoptosis, and autophagy. The drug influences various signaling pathways, including phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK), and Janus kinase (JAK)/signal transducer and activator of transcription (STAT). It also promotes melanin production, increases photosensitivity, improves tyrosinase activity, enhances local skin microcirculation, and stimulates melanocyte proliferation. The formulation is composed of several traditional Chinese herbs, including Angelica sinensis, peach kernel, safflower, astragalus, Panax notoginseng, Fangfeng, Angelica dahurica, red peony root, peony bark, purslane, and atractylodes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bailing tablet.